Physician profile
Lindsey E Richards
NPI 1710373105
$9,658.32
in general payments reported to CMS, 2019-2025
29 companies · $2,439 in 2025
The $2,439 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $722 · 2021: $818 · 2022: $1,960 · 2023: $1,510 · 2024: $1,956 · 2025: $2,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,512 · Education: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,512.49 |
| Education | $393.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,408.05 | 2020-2025 | Tremfya, Simponi, Remicade |
| Abbvie INC. | $1,267.16 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $931.50 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $893.66 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Almirall LLC | $527.40 | 2020-2025 | Seysara, Klisyri |
| Leo Pharma INC. | $443.98 | 2019-2025 | Adbry |
| Merz North America, INC. | $441.07 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $416.37 | 2020-2024 | Blu-U, Odomzo |
| Pfizer INC. | $405.58 | 2021-2025 | |
| Genzyme Corporation | $354.49 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $325.02 | 2019-2025 | |
| Incyte Corporation | $281.62 | 2021-2025 | Opzelura |
| Biofrontera INC. | $267.33 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Amgen INC. | $227.82 | 2020-2024 | Otezla |
| Ucb, INC. | $215.30 | 2022-2025 | Bimzelx |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $211.83 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $198.34 | 2020-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $176.52 | 2020-2025 | Cabtreo |
| Allergan, INC. | $155.96 | 2020-2022 | |
| Lilly USA, LLC | $123.82 | 2019-2024 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $116.85 | 2023-2025 | Zoryve |
| Revance Therapeutics, INC. | $100.51 | 2025 | Daxxify |
| Medimetriks Pharmaceuticals, INC. | $44.92 | 2019-2022 | |
| Dermira, INC. | $34.05 | 2020-2021 | |
| Epi Health, LLC | $24.31 | 2021 | |
| Verrica Pharmaceuticals INC. | $21.19 | 2024 | Ycanth |
| Journey Medical Corporation | $18.36 | 2023 | |
| Botanix Sb INC | $14.69 | 2025 | Sofdra |
| Organon LLC | $10.62 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.